Skip to main content
Top
Published in: HSS Journal ® 2/2008

01-09-2008 | Original Article

Von Willebrand Factor, Red Cell Fragmentation, and Disease Activity in Systemic Lupus Erythematosus

Authors: Rodolfo V. Curiel, MD, Rajkumari Bhagati, MD, Lakshmi Basavaraju, MD, Delona Norton, MPH, James Katz, MD, Elizabeth Haile, MS, Arthur Weinstein, MD

Published in: HSS Journal ® | Issue 2/2008

Login to get access

Abstract

This study sought to determine whether the plasma levels of Von Willebrand factor (vWf) and the degree of red blood cell (RBC) fragmentation on peripheral smear correlate with disease activity in systemic lupus erythematosus (SLE). Forty consecutive patients who fulfilled the criteria for SLE were studied prospectively for 1 year. Patients were categorized according to the SLE Disease Activity Index (SLEDAI) as either active (>2) or inactive disease and followed up monthly (active) or quarterly (inactive). At each visit, patients were examined fully and had complete blood count, tests on antibodies to double-stranded DNA, C3, and C4 levels, and urinalysis. Citrated plasma was analyzed for vWf antigen by standard enzyme-linked immunosorbent assay. A Wright’s stained blood smear was obtained and schistocytes were quantitated on blood smear. The number of schistocytes per 500 RBCs was determined and a schistocyte index (SI) was calculated. At baseline, vWf correlated with SLEDAI (r = 0.64, p < 0.01), SI correlated with SLEDAI (r = 0.62, p < 0.01), and vWf and SI correlated with each other (r = 0.41, p = 0.01). There was an inverse correlation between baseline C3 levels and vWf (r = 0.49, p = 0.0013) and C3 levels and SI (r = 0.40, p = 0.01). Over time, there was also a correlation of SLEDAI with vWf (r = 0.53, p = 0.002) and SI (r = 0.57;p = 0.002). The relation of vWf with SI approached but did not reach statistical significance (r = 0.37, p = 0.06). We found that the plasma levels of vWf and the degree of RBC fragmentation correlate with lupus disease activity over time. Therefore, inflammation in SLE may be associated with endothelial injury.
Literature
2.
go back to reference Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 44(5):1203–1208PubMedCrossRef Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 44(5):1203–1208PubMedCrossRef
3.
go back to reference Bridoux F, Vrtovsnik F, Noel C, Saunier P, Mougenot B, Lemaitre V, Dracon M, Lelievre G, Vanhille P (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term survival. Nephrol Dial Transplant 13(2):298–304 doi:10.1093/ndt/13.2.296 PubMedCrossRef Bridoux F, Vrtovsnik F, Noel C, Saunier P, Mougenot B, Lemaitre V, Dracon M, Lelievre G, Vanhille P (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term survival. Nephrol Dial Transplant 13(2):298–304 doi:10.​1093/​ndt/​13.​2.​296 PubMedCrossRef
4.
go back to reference Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8):914–918PubMed Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8):914–918PubMed
5.
go back to reference Manadan AM, Harris C, Schwartz MM, Block JA (2003) The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy. J Rheumatol 30(6):1227–1230PubMed Manadan AM, Harris C, Schwartz MM, Block JA (2003) The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy. J Rheumatol 30(6):1227–1230PubMed
7.
go back to reference Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 349:2399–2406 doi:10.1056/NEJMoa035471 PubMedCrossRef Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 349:2399–2406 doi:10.​1056/​NEJMoa035471 PubMedCrossRef
8.
go back to reference Al-Herz A, Ensworth S, Shojania K, Esdaile JM (2003) Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30(3):493–496PubMed Al-Herz A, Ensworth S, Shojania K, Esdaile JM (2003) Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30(3):493–496PubMed
10.
go back to reference Panza JA (1994) Endothelium-dependent vasodilatation and essential hypertension. N Engl J Med 331(14):951PubMedCrossRef Panza JA (1994) Endothelium-dependent vasodilatation and essential hypertension. N Engl J Med 331(14):951PubMedCrossRef
11.
go back to reference Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29(2):292–297PubMed Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29(2):292–297PubMed
12.
go back to reference Paleolog EM, Crossman DC, Mc Vey JH, Pearson JD (1990) Differential regulation by cytokines of constitutive and stimulated secretion of Von Willebrand factor from endothelial cells. Blood 75(3):688–695PubMed Paleolog EM, Crossman DC, Mc Vey JH, Pearson JD (1990) Differential regulation by cytokines of constitutive and stimulated secretion of Von Willebrand factor from endothelial cells. Blood 75(3):688–695PubMed
13.
go back to reference Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, Van Gendern PJ, Fijnheer R (1999) Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial perturbation. Blood 94(1):179–185PubMed Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, Van Gendern PJ, Fijnheer R (1999) Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial perturbation. Blood 94(1):179–185PubMed
14.
go back to reference Blann AD (2006) Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95(1):49–55PubMed Blann AD (2006) Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95(1):49–55PubMed
15.
go back to reference Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E (2005) Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26(5):440–446 doi:10.1093/eurheartj/ehi104 PubMedCrossRef Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E (2005) Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26(5):440–446 doi:10.​1093/​eurheartj/​ehi104 PubMedCrossRef
18.
go back to reference Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM (2001) Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis. Arthritis Res 3(3):178–182 doi:10.1186/ar295 PubMedCrossRef Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM (2001) Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis. Arthritis Res 3(3):178–182 doi:10.​1186/​ar295 PubMedCrossRef
21.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640 doi:10.1002/art.1780350606 PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640 doi:10.​1002/​art.​1780350606 PubMedCrossRef
22.
go back to reference Rick ME, Moll S, Taylor MA, Krizek DM, White GC 2nd, Aronson DL (2002) Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 88(4):598–604PubMed Rick ME, Moll S, Taylor MA, Krizek DM, White GC 2nd, Aronson DL (2002) Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 88(4):598–604PubMed
24.
go back to reference Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL (2004) Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS-13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 75(2):96–100 doi:10.1002/ajh.10457 PubMedCrossRef Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL (2004) Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS-13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 75(2):96–100 doi:10.​1002/​ajh.​10457 PubMedCrossRef
25.
go back to reference Ibañez D, Gladman D, Urowitz M (2007) Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J Rheumatol 34(2):336–340PubMed Ibañez D, Gladman D, Urowitz M (2007) Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J Rheumatol 34(2):336–340PubMed
26.
go back to reference Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD, LUMINA Study Group (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA).XXIII. Baseline predictors of vascular events. Arthritis Rheum 50(12):3947–3957 doi:10.1002/art.20622 PubMedCrossRef Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD, LUMINA Study Group (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA).XXIII. Baseline predictors of vascular events. Arthritis Rheum 50(12):3947–3957 doi:10.​1002/​art.​20622 PubMedCrossRef
27.
go back to reference Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guerin V, Boisseau MR, Conri C (2003) Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 30(9):1963–1966PubMed Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guerin V, Boisseau MR, Conri C (2003) Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 30(9):1963–1966PubMed
28.
go back to reference Moscato S, Pratesi F, Bongiorni F, Scavuzzo MC, Chimenti D, Bombardieri S, Migliorini P (2002) Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun 18(3):231–238 doi:10.1006/jaut.2002.0583 PubMedCrossRef Moscato S, Pratesi F, Bongiorni F, Scavuzzo MC, Chimenti D, Bombardieri S, Migliorini P (2002) Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun 18(3):231–238 doi:10.​1006/​jaut.​2002.​0583 PubMedCrossRef
29.
go back to reference Yazici ZA, Raschi E, Patel A, Testoni C, Borghi MO, Graham AM, Meroni PL, Lindsey N (2001) Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immunol 13(3):349–357 doi:10.1093/intimm/13.3.349 PubMedCrossRef Yazici ZA, Raschi E, Patel A, Testoni C, Borghi MO, Graham AM, Meroni PL, Lindsey N (2001) Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immunol 13(3):349–357 doi:10.​1093/​intimm/​13.​3.​349 PubMedCrossRef
30.
go back to reference Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A (2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43(7):924–929 doi:10.1093/rheumatology/keh213 CrossRef Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A (2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43(7):924–929 doi:10.​1093/​rheumatology/​keh213 CrossRef
31.
go back to reference Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR (2004) Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93(2):198–200PubMedCrossRef Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR (2004) Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93(2):198–200PubMedCrossRef
Metadata
Title
Von Willebrand Factor, Red Cell Fragmentation, and Disease Activity in Systemic Lupus Erythematosus
Authors
Rodolfo V. Curiel, MD
Rajkumari Bhagati, MD
Lakshmi Basavaraju, MD
Delona Norton, MPH
James Katz, MD
Elizabeth Haile, MS
Arthur Weinstein, MD
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
HSS Journal ® / Issue 2/2008
Print ISSN: 1556-3316
Electronic ISSN: 1556-3324
DOI
https://doi.org/10.1007/s11420-008-9080-9

Other articles of this Issue 2/2008

HSS Journal ® 2/2008 Go to the issue